Oncology Intelligence
OI 2014 is a key update over previous report OI 2013, as it may covers 398 more oncology drug developers than the previous report. It also abandoned 91 companies, which were earlier covered in OI 2013, which were either acquired/merged or closed during the period.
providing intelligence at fingertips
Largest Coverage with 33 Countries covered Globally
523 Clinical, 360 Preclinical & 48 Discovery Companies Profiles
Individual Drug Mechanism of Action & Drug Target
Emerging Cancer Drug Targets Details
1055 pages full of insights
Today Cancer Research comprises the largest set of drugs in development with equal increasing robust number of drug developers. Similarly with span of time due to numerous factors, abandoned rate of drugs / developers are also increasing, thus altogether making it time taking process to identify actionable intelligence in this highly technology driven domain.
Oncology Drug Report 2014 –World’s Largest Active Resource for Decision Making, is designed to curtail down the efforts in identifying the real picture of present cancer drug development market, by bringing more authentic data under review and eliminating the undesired information.
Report for the first time identifies and profiles 931 Active Cancer Drug Development companies from 33 countries worldwide, developing 2237 cancer-targeting drugs. It evaluates 19 major cancer indications drug development pipeline and analysis it to provide thousands of active clinical trials information; cancer drug targets, molecule types etc., thus all together to bring the most updated and robust information at the fingertips. It creates immense authentic knowledgebase (all information with references) on thousands of Proprietary technologies, M&A deals and partnering occurring in cancer domain in last 10 years.
A Single Innovative and Unique Report provide Answers to Many: –
Oncology Drug Report 2014, is the second updated edition, and its preceding last year release – Oncology Intelligence 2013, covered 624 companies, with 1600+ molecules in development, and was a highly successful report. This new edition covers some 378 more companies and eliminates 65 companies, which were either acquired/merged or had abandoned their oncology drug development program.
Table of Content:-
List of Figures
List of Tables
List of Boxes
List of Clinical Companies
List of Pre-clinical Companies
List of Discovery Companies
Executive Summary.
Section A : Oncology Companies with Active Drug Development Pipeline – Infographics
—Worldwide Distribution of Companies with A ctive Cancer Drug Pipeline
Quantitative Estimation of Cancer Drug Developers present in U.S.A vs. Europe vs. Asia vs. Canada vs. Australia vs. Rest of the World (931 Companies)
Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in U.S.A (468 companies)
Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in Europe (270 companies)
Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in Asia (132 companies)
—Country-wise Distribution of Companies (Clinical, Preclinical & Discovery) having Active Cancer Drug Development Pipeline in Europe and Asia Region.
To identify best and emerging countries, for promoting cancer drug development in the region.
— State-wise Distribution of Companies (Clinical, Preclinical & Discovery) having Active Cancer Drug Development Pipeline in U.S.A.
To explore the Top cancer innovation supporting States in United States.
— Distribution of 931 companies, on the basis of year of Establishment
To explore the emergence of Cancer Drug Discovery And Development.
— Quantitative Estimation of Oncology Drug Developers on the basis of Human Resource Employed.
Top 10 cancer drug development companies (in terms of employee numbers), with their total employees vs. total number of R&D staff for past three consecutive years.
Section B : Active Oncology Drugs and Targets in Development – Key Intelligence
— Distribution of Oncology Molecules in Clinical Development (2237 molecules)
Total number of Small, Biologics and Non Biological complex molecules in clinical development.
Total number of cancer molecules in development in USA, Europe, Asia and Rest of the World.
Molecule development strategies – Top 10 companies vs. remaining 921 companies.
— Top 20 Oncology Drug Development Companies (In terms of molecules in Clinical Development)
Top 20 Cancer clinical development companies, their molecule types (small, biologics & NBCM),
clinical phases and total Indications of development.
— Monoclonal Antibodies in Clinical Development (173 molecules)
Monoclonal antibodies in clinical development with developer and partner name, antibody target, isotype and drug development indications.
— Monoclonal Antibodies in Pre-Clinical Development (193 molecules)
Monoclonal antibodies in preclinical & discovery development with developer name, antibody target and drug development indications.
— Cancer Vaccines in Clinical Development (134 molecules)
Cancer Vaccines in clinical development with short description, developer and partner name, drug target and development Indications.
— Cancer Vaccines in Pre-Clinical Development (50 molecules)
Cancer Vaccines in Pre-clinical & Discovery development with developer name, drug target and development Indications.
— Cancer Targeting Antibodies Drug Conjugates in Clinical Development (42 molecules)
ADCs in clinical development, with short description of antibody and toxin attached; developer and partner name; its target and development Indications.
— Cancer Targeting Radio-Immuno Conjugates in Clinical Development (10 molecules)
Radio-Immuo Conjugates in clinical development, with short description of antibody and radio isotope attached; developer and partner name; its target and development Indications.
— Cancer Targeting Recombinant/Fusion Protein Therapies in Development (49 molecules)
Recombinant/Fusion Protein in clinical development with short description, developer and partner name, their targets and development Indications.
— Cancer Targeting Synthetic Peptides in Clinical Development (19 molecules)
Synthetic peptides/proteins in clinical development with short description, developer and partner name, their targets and development Indications.
— Oncolytic Virus Based/Gene Therapies in Clinical Development (33 molecules)
Oncolytic virus based Therapies in clinical development with short description, its developer and partner name; drug target and development Indications.
— Cell Based Therapies for cancer treatment in Clinical Development (19 molecules)
T-Cell, Stem Cell and Other Cell based therapies in clinical development with short description, its developer and partner name; drug target and development Indications.
— Other Biological Therapies in Clinical Development (23 molecules)
Remaining biological therapies in clinical development for cancer treatment, with short description, their developer and partner name; drug target and development Indications.
— Protein Kinases – An Emerging Class of Cancer Drug Targets
Protein kinases vs other cancer drug targets in clinical development;
Comparative developmental profile of protein kinases, with their molecules and indications numbers.
Top four kinases classes targeting cancer with their molecule numbers;
Cancer targeting kinases development strategies – Top 10 companies vs. Remaining 921 companies.
Established kinases in cancer drug discovery, their FDA approval years; Annual sales and indications.
Anticipated protein kinases launch In 2014-15, with cancer indications.
— Complete List of Emerging Cancer Drug Targets (228 Targets)
Protein Kinases as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. (55 Major Protein Target Classes)
Tumor Necrosis Factors as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular
Location & Functions, Short Description with drugs in clinical development for the target. (11 Major Protein Targets)
G-coupled Receptors as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. (9 Major Protein Targets)
Tumor Surface Antigens as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. (22 Major Protein Targets)
Transcription Factors as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular
Location & Functions, Short Description with drugs in clinical development for the target. (14 Major Protein Targets)
Targeting Cellular Metabolites as Cancer Drug Targets –Target Name, Gene, Protein Family,
Cellular Location & Functions, Short Description with drugs in clinical development for the target. (14 Major Protein Targets)
Growth Factor as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development. (8 Major Protein Targets)
Miscellaneous Other Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development. (95 Targets)
Section C : Oncology Indications in various Developmental Stages- Intelligence
—Distribution of Oncology Indications in Clinical Development (4264 indications)
Division of 4264 indications for 2237 Molecules, in drugs types – Small, Biologic and NBCM.
Geographic distribution of Clinical Indications and its correlation with number of molecules from similar region in development; Phase-Wise Breakup of total Indications;
Cancer Clinical Indications strategies – Top 10 companies vs. remaining 513 companies;
Comparative analysis on the preference of Top 10 companies for Small Molecule Vs. Biologics, in compare to remaining 513 companies.
— Drug Development Strategies- Top 10 Companies vs. Remaining 921 Companies
A competitive intelligence de-marking the preference of Large Pharma Majors to Small Innovators – their choice of targets; cancer indications and types of molecules development.
–Drug Development Profile & Pipeline Analysis – Lung Cancer
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:– NSCLC
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Monoclonal Antibodies, Vaccines and other Biologics in development.
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Strong Pipeline Companies with highest number of molecules against NSCLC;
Top 10 companies vs. others strategies in Lung Cancer Drug Development.
Pipeline Analysis:– SCLC
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
— Drug Development Profile & Pipeline Analysis – Breast Cancer
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Monoclonal Antibodies, Vaccines and other Biologics in development.
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Strong Pipeline Companies with highest number of molecules against Breast cancer;
Top 10 companies vs. others strategies in Breast Cancer Drug Development.
—Drug Development Profile & Pipeline Analysis – Colorectal Cancer
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Monoclonal Antibodies, Vaccines and other Biologics in development.
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Strong Pipeline Companies with highest number of molecules against Colorectal cancer;
Top 10 companies vs. others strategies in Colorectal Cancer Drug Development.
—Drug Development Profile & Pipeline Analysis – Melanoma Cancer
An Overview to Disease, Epidemiology; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Monoclonal Antibodies, Vaccines and other Biologics in development.
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Strong Pipeline Companies with highest number of molecules against Melanoma cancer;
Top 10 companies vs. others strategies in Melanoma Cancer Drug Development.
Drug Development Pipeline:– Other Skin Cancers including Non-Melanoma Cancers.
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
—Drug Development Profile & Pipeline Analysis – Prostate Cancer
An Overview to Disease, Epidemiology; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Monoclonal Antibodies, Vaccines and other Biologics in development.
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Strong Pipeline Companies with highest number of molecules against Prostate cancer;
Top 10 companies vs. others strategies in Prostate Cancer Drug Development.
—Drug Development Profile & Pipeline Analysis – Ovarian Cancer
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Monoclonal Antibodies, Vaccines and other Biologics in development.
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Strong Pipeline Companies with highest number of molecules against Ovarian cancer;
Top 10 companies vs. others strategies in O varian Cancer Drug Development.
Drug Development Pipeline:– Gynaecologic Malignancies.
Cervical Cancer – Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).
Fallopian Tube Cancer -Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).
Peritoneal Cancer – Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).
Endometrial Cancer – Detailed Ph III, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
–Drug Development Profile & Pipeline Analysis – Pancreatic Cancer
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Monoclonal Antibodies, Vaccines and other Biologics in development.
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Strong Pipeline Companies with highest number of molecules against Pancreatic cancer;
Top 10 companies vs. others strategies in Pancreatic Cancer Drug Development.
Drug Development Pipeline:– Gastrointestinal Tract Cancers.
Oesophageal Cancer- Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).
Biliary Tract Cancer -Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).
Gallbladder Cancer – Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).
Cholangiocarcinoma -Detailed Ph III, Ph II, Ph I & preclinical Pipeline (including developers, partners & targets).
Anal Cancer – Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).
Gastrointestinal Stromal Tumor- Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).
— Drug Development Profile & Pipeline Analysis – Hepatocellular Carcinoma
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
— Drug Development Profile & Pipeline Analysis – Gastric Cancer
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
— Drug Development Profile & Pipeline Analysis – Multiple Myeloma
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
— Drug Development Profile & Pipeline Analysis – Leukemia
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Pipeline Analysis:– Leukemia
Acute Myeloid Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
Acute Myelogenous Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
Acute Lymphoid Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
Acute Lymphocytic Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
Chronic Myeloid Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
Chronic Myelogenous Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
Chronic Myelomonocytic Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
Chronic Lymphoid Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
—Drug Development Profile & Pipeline Analysis – Non-Hodgkin Lymphoma
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Pipeline Analysis:– Waldenstrom’s Macroglobulinemia
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
— Drug Development Profile & Pipeline Analysis – Hodgkin Lymphoma
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
—Drug Development Profile & Pipeline Analysis- Brain Cancer (including Glioblastoma)
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:– Glioblastoma
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Neuroblastoma – Detailed PhIII, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).
Medulloblastoma – Detailed PhIII, Ph II, Ph I, Preclinical Pipeline (including developers, partners & targets).
Anaplastic Astrocytoma- Detailed PhIII, Ph II, Ph I Pipeline (including developers, partners & targets).
— Drug Development Profile & Pipeline Analysis- Head & Neck Cancer
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:– Glioblastoma
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Nasopharynx Cancer– Detailed PhIII, Ph II, Ph I Pipeline (including developers, partners & targets).
Oral Cancer- Detailed PhIII, Ph II, Ph I, Preclinical Pipeline (including developers, partners & targets).
— Drug Development Profile & Pipeline Analysis – Renal Cell Carcinoma
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Wilm’s Tumor – Detailed PhIII, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).
— Drug Development Profile & Pipeline Analysis – Bladder Cancer
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
— Drug Development Profile & Pipeline Analysis – Thyroid Cancer
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
— Drug Development Profile & Pipeline Analysis – Sarcoma
An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:–
Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
— Other Rare Cancer Indications – Developmental Pipeline Detailed PhIII, Ph II, Ph I, Pre
clinical & Discovery Pipeline (including developers, partners, targets and indications).
—Orphan Drug Status drugs in development for Cancer Treatment
Name of Drug and Developer, its Orphan drug Indications and Orphan status providing agencies –
US FDA and EMEA.
— US FDA New Oncology Drug Approvals – 2013
Developer, Approval month, Partner, Drug’s Proprietary Name, Approved Indication.
— Oncology Clinical Pipeline – Major Phase III Failures – 2013
Ph III Molecules-Key Partners & expected Launch ; Ph II & Ph I Clinical Pipeline (including partners).
Section D : Individual Oncology Company Profile (with Active Clinical Pipeline)
— A to Z Alphabetical Profiles of Cancer Clinical Drug Developer Companies (523 Companies)
Individual company Pages includes: Company Profile – Key technology platform, Oncology centred deals, collaborations and business insights, key investors and key partners.
Clinical Pipeline Profile– Drug name, its target description, various development indications for cancer cure with current clinical trials and trials status (Active, Recruiting, Completed etc), FDA/EMEA Orphan drug status, Special Protocol Assessment, fast track approvals etc; company’s pre-clinical & discovery pipeline.
Management Profile –Address, Contact phone number, e-mail, employees number range, Key Decision Maker (CXOs) names, designation with e-mail & LinkedIn IDs,, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on May 2014).
Section E : Individual Oncology Company Profile (with Active PreClinical Pipeline)
— A to Z Alphabetical Profiles of Cancer Preclinical Drug Developer Companies (360 Companies)
Individual company Pages includes: Company Profile – Key technology platform, Oncology centered deals, collaborations and business insights, key investors and key partners.
Pre-Clinical Pipeline Profile – Drugs name, its targets, with details of its development for various indications for cancer cure, FDA/EMEA Orphan drug status, company’s pre-clinical pipeline.
Management Profile –Address, Contact phone number, e-mail, employees number range, key management people (CXOs) name and designation, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on May 2014).
Section F : Individual Oncology Company Profile (with Active Discovery Pipeline)
☐ A to Z Alphabetical Profiles of Cancer Discovery stage Companies (48 Companies)
Individual company Pages includes: Company Profile – Key technology platform, Oncology centred deals, collaborations and business insights, key investors and key partners.
Discovery Pipeline Profile – Drug name, its targets, with details, of its development for various indications for cancer cure.
Management Profile –Address, Contact phone number, e-mail, employees number range, key management people (CXOs) name and designation, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on May 2014).
Appendix A: Country Wise List of 931 Companies.
Appendix B: Complete 2237 Molecules List, along with their Developer’s Name.
Figure A.1 Qualitative Estimation of Oncology Drug Developers present in U.S.A vs. Europe vs. Asia vs. Australia vs. Canada vs. Rest of the World (931 Active Companies).
Figure A.2 Quantitative Estimation of clinical, preclinical & discovery companies present in U.S.A (468 companies
Figure A.3 Quantitative Estimation of clinical, preclinical & discovery companies present in Europe (270 companies)
Figure A.4 Quantitative Estimation of clinical, preclinical & discovery companies present in Asia (132 companies)
Figure A.5 Showing all individual 19 Countries in Europe and 8 Countries in Asia, along with the individual oncology focused companies present in these countries.
Figure A.6 Bar Graph for Country-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in Europe Region.
Figure A.7 Bar Graph for Country-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in Asia Region.
Figure A.8 Showing all individual 28 States in U.S.A, along with the individual number of oncology focused companies present in these States.
Figure A.9 Bar Graph for State-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in U.S.A
Figure A.10 Distribution of Active Cancer Drug Developers on the basis of year of Formation/Incorporation.
Figure A.11 Bar Graph showing incorporation pattern of cancer drug developers form 1991 onwards.
Figure A.12 Division of 931 cancer drug development companies on the basis of Human Resource employed.
Figure B.1 Distribution of Active Cancer Molecules in various Developmental Stages among Small, Biologics & others (2237 Molecules).
Figure B.2 Division of total cancer molecules in development among U.S.A, Europe, Asia & Rest of the World.
Figure B.3 Molecule Development Strategies:-
Figure B.4 Clinical phase-wise (Ph I/PhII/PhIII), Preclinical & Discovery stage distribution of 2237 molecules.
Figure B.5 Phase-wise distribution of Small Molecules in various developmental stages for cancer treatment.
Figure B.6 Phase-wise distribution of Biologics in various developmental stages for cancer treatment.
Figure B.7 Clinical phase-wise division of cancer molecules in development in U.S.A, Europe, Asia & RoW.
Figure B.8 Protein Kinase in cancer drug development
C . Clinical phase-wise distribution of Protein Kinases in cancer drug development.
Figure B.9 Distribution of total Kinases in cancer clinical development in U.S.A, Europe, Asia & RoW.
Figure B.10 Top four Protein Kinases (Targets) in cancer clinical drug development (w.r.t molecules in development).
Figure B.11 Top three cancer Indications with highest numbers of Protein Kinases in clinical development.
Figure B.12 Protein Kinases Molecules development Strategies:-
Figure C.1 Distribution of Total Oncology Indications in various Development (4264 Active Cancer Drug Indications for 2231 Cancer Drugs under development)
Figure C.2 Distribution of 4264 cancer drug development indications among USA, Europe, Asia and RoW.
Figure C.3 Cancer Clinical Indications Development Strategies:-
Figure C.4 Global incidence of Lung Cancer.
Figure C.5 A. Lung Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.
Figure C.6 Exploring Lung Cancer Development Strategies:-
Figure C.7 A. Phase-wise division of total Lung Cancer molecules in various developmental stages.
Figure C.8 A. Distribution of Lung Cancer Pipeline in Small, Biologics & NBCM.
Figure C.9 Global incidence of Breast Cancer.
Figure C.10 A. Breast Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.
Figure C.11 Exploring Breast Cancer Development Strategies:-
Figure C.12 A. Phase-wise division of total Breast Cancer molecules in various developmental stages.
Figure C.13 A. Distribution of Breast Cancer Pipeline in Small, Biologics & NBCM.
Figure C.14 Global incidence of Colorectal Cancer.
Figure C.15 A. Colorectal Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.
Figure C.16 Exploring Colorectal Cancer Development Strategies:-
Figure C.17 A. Phase-wise division of total Colorectal Cancer molecules in various developmental stages.
Figure C.18 A. Distribution of Colorectal Cancer Pipeline in Small, Biologics & NBCM.
Figure C.19 Global incidence of Melanoma Cancer.
Figure C.20 A. Melanoma Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.
Figure C.21 Exploring Melanoma Cancer Development Strategies:-
clinical companies pipeline molecules.
Figure C.22 A. Phase-wise division of total Melanoma Cancer molecules in various developmental stages.
Figure C.23 A. Distribution of Melanoma Cancer Pipeline in Small, Biologics & NBCM.
Figure C.24 Global incidence of Prostate Cancer.
Figure C.25 A. Prostate Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.
Figure C.26 Exploring Prostate Cancer Development Strategies:-
Figure C.27 A. Phase-wise division of total Prostate Cancer molecules in various developmental stages.
Figure C.28 A. Distribution of Prostate Cancer Pipeline in Small, Biologics & NBCM.
Figure C.29 Global incidence of Ovarian Cancer.
Figure C.30 A. Ovarian Cancer treatment molecules vs. total number of molecules in various developmental stages for cancer treatment.
Figure C.31 Exploring Ovarian Cancer Development Strategies:-
Figure C.32 A. Phase-wise division of total Ovarian Cancer molecules in various developmental stages.
Figure C.33 A. Distribution of Ovarian Cancer Pipeline in Small, Biologics & NBCM.
Figure C.34 Global incidence of Pancreatic Cancer.
Figure C.35 A. Pancreatic Cancer treatment molecules vs. total number of molecules in various developmental stages for cancer treatment.
Figure C.36 Exploring Pancreatic Cancer Development Strategies:-
Figure C.37 A. Phase-wise division of total Pancreatic Cancer molecules in various development stages.
Figure C.38 A. Distribution of Pancreatic Cancer Pipeline in Small, Biologics & NBCM.
Figure C.39 Global incidence of Hepatocellular Carcinoma.
Figure C.40 Global incidence of Gastric Cancer.
Figure C.41 Global incidence of Multiple Myeloma.
Figure C.42 Global incidence of Leukemia.
Figure C.43 Global incidence of Non-Hodgkin Lymphoma.
Figure C.44 Global incidence of Hodgkin Lymphoma.
Figure C.45 Global incidence of Brain Cancer including Glioblastoma.
Figure C.46 Global incidence of Head & Neck Cancer.
Figure C.47 Global incidence of Renal Cell Carcinoma.
Figure C.48 Global incidence of Bladder Cancer.
Figure C.49 Global incidence of Thyroid Cancer.
Table A.1 Top 10 Cancer drug development companies (in terms of employee number).
Table B.1 Top 20 companies with highest number of cancer clinical molecules in development.
Table B.2 Monoclonal Antibodies in Clinical Trials (174 Molecules- their developer, partner, target, isotypes & indications).
Table B.3 Monoclonal Antibodies in Preclinical & Discovery stage (193 Molecules- their developer, target & indications).
Table B.4 Cancer Vaccines in Clinical development (134 Vaccines-their developer, partner, target, indications & comments).
Table B.5 Cancer Vaccines in Preclinical & Discovery development stage (50 Vaccines-their developer, target & indications).
Table B.6 Antibody Drug Conjugates in Clinical development (42 Molecules, developer, partner, target, indications & comments).
Table B.7 Radio-Immuno Conjugates in Clinical Development (10 Molecules, developer, partner, target, indications, comments).
Table B.8 Recombinant/Fusion Proteins based therapies in Clinical Development (49 Molecules, developer, partner, target, indications, comments).
Table B.9 Synthetic Peptides based therapies in Clinical Trials (19 Molecules, developer, partner, target, indications, comments).
Table B.10 Gene Therapies & Oncolytic based therapies in Clinical Development (33 Molecules, developer, partner, target, indications, comments).
Table B.11 T cell based therapies in Clinical Trials (8 Molecules, developer, partner, target, indications, comments).
Table B.12 Stem cell based therapies in Clinical Trials (6 Molecules, developer, partner, target, indications, comments).
Table B.13 Other cell based therapies in Clinical Trials (5 Molecules, developer, partner, target, indications, comments).
Table B.14 Miscellaneous other Biologics in Clinical Trials (19 Molecules, developer, partner, target, indications, comments).
Table B.15 Approved Kinase Inhibitors for Cancer Cure (Developer, type, target, approved since, 2013 sales, indications).
Table B.16 Expected New Kinases Launches in 2014-15 (Drug, developer, type, target, expected launch & indication).
Table B.17 Cancer Drug Targets – Protein Kinases (Individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s description).
Table B.18 Cancer Drug Targets – Tumor Necrosis Factor Family (Individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s Description).
Table B.19 Cancer Drug Targets – G-coupled Protein Receptors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s Description).
Table B.20 Cancer Drug Targets – Tumor Antigens (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s Description).
Table B.21 Cancer Drug Targets – Transcription Factors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s Description).
Table B.22 Cancer Drug Targets – Metabolic Enzymes (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s Description).
Table B.23 Cancer Drug Targets – Growth Factors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target Description).
Table B.24 Cancer Drug Targets – Miscellaneous other Targets (individual target name, Gene, protein family, Drugs in development for the target, target Description).
Table C.1 Molecule Development Strategies – Top 10 companies Vs. Remaining 921 companies
(Comparison between total molecules, clinical phases, types, top 7 targets, top 9 indications and market capitalization).
Table C.2 Top selling chemotherapies for Lung Cancer.
Table C.3 Top selling targeted therapies for Lung Cancer.
Table C.4 Molecules in Ph III clinical trials for NSCLC (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.5 Monoclonal Antibodies in various drug development stages for the treatment of Lung Cancer.
Table C.6 Vaccines in various drug development stages for the treatment of Lung Cancer.
Table C.7 Miscellaneous other Biologics in various drug development stages for the treatment of Lung Cancer.
Table C.8 Non Small Lung Cancer (NSCLC) Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.9 Molecules in Ph III clinical trials for Lung Cancer (SCLC) (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).
Table C.10 Small Cell Lung Cancer (SCLC) Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.11 Top selling Chemotherapies/Hormonal Therapies for Breast Cancer.
Table C.12 Top selling Targeted Therapies for Breast Cancer.
Table C.13 Molecules in Ph III clinical trials for Breast Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).
Table C.14 Monoclonal Antibodies in various drug development stages for the treatment of Breast Cancer.
Table C.15 Vaccines in various drug development stages for the treatment of Breast Cancer.
Table C.16 Miscellaneous other Biologics in various drug development stages for the treatment of Breast Cancer.
Table C.17 Breast Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.18 Top selling chemotherapies for Colorectal Cancer.
Table C.19 Top selling targeted therapies for Colorectal Cancer.
Table C.20 Molecules in Ph III clinical trials for Colorectal Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).
Table C.21 Monoclonal Antibodies in various drug development stages for the treatment of Colorectal Cancer.
Table C.22 Vaccines in various drug development stages for the treatment of Colorectal Cancer.
Table C.23 Miscellaneous other Biologics in drug development stages for the treatment of Colorectal Cancer.
Table C.24 Colorectal Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.25 Top selling chemotherapies for Melanoma Cancer.
Table C.26 Top selling targeted therapies for Melanoma Cancer.
Table C.27 Molecules in Ph III clinical trials for Melanoma Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).
Table C.28 Monoclonal Antibodies in various drug development stages for the treatment of Melanoma Cancer.
Table C.29 Vaccines in various drug development stages for the treatment of Melanoma Cancer.
Table C.30 Miscellaneous other Biologics in drug development stages for the treatment of Melanoma Cancer.
Table C.31 Melanoma Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.32 Other Skin Cancers Including Non-Melanoma Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.33 Top selling Chemotherapies for Prostate Cancer.
Table C.34 Top selling Targeted therapies for Prostate Cancer.
Table C.35 Molecules in Ph III clinical trials for Prostate Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).
Table C.36 Monoclonal Antibodies in various drug development stages for the treatment of Prostate Cancer.
Table C.37 Vaccines in various drug development stages for the treatment of Prostate Cancer.
Table C.38 Miscellaneous other Biologics in drug development stages for the treatment of Prostate Cancer.
Table C.39 Prostate Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.40 Top selling chemotherapies for Ovarian Cancer.
Table C.41 Molecules in Ph III clinical trials for Ovarian Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).
Table C.42 Monoclonal Antibodies in various drug development stages for the treatment of Ovarian Cancer.
Table C.43 Vaccines in various drug development stages for the treatment of Ovarian Cancer.
Table C.44 Miscellaneous other Biologics in drug development stages for the treatment of Ovarian Cancer.
Table C.45 Ovarian Cancer Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.46 Cervical Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.47 Fallopian Tube Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.48 Peritoneal Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.49 Endometrial Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.50 Top selling chemotherapies for Pancreatic Cancer.
Table C.51 Top selling targeted therapies for Pancreatic Cancer.
Table C.52 Molecules in Ph III clinical trials for Pancreatic Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).
Table C.53 Monoclonal Antibodies in various drug development stages for the treatment of Pancreatic Cancer.
Table C.54 Vaccines in various drug development stages for the treatment of Pancreatic Cancer.
Table C.55 Miscellaneous other Biologics in drug development stages for the treatment of Pancreatic Cancer.
Table C.56 Pancreatic Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.57 Neuroendocrine Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.58 Esophageal Cancer Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.59 GastroIntestinal Stromal Tumor Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.60 Biliary Tract Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.61 Gall Bladder Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.62 Midgut Carcinoid Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.63 Cholangiocarcinoma Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.64 Anal Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.65 Top selling targeted therapies for Hepatocellular Carcinoma.
Table C.66 Molecules in Ph III clinical trials for Hepatocellular Carcinoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.67 Hepatocellular Carcinoma Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.68 Top selling targeted therapies for Gastric Cancer.
Table C.69 Molecules in Ph III clinical trials for Gastric Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.70 Gastric Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.71 Molecules in Ph III clinical trials for Multiple Myeloma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.72 Multiple Myeloma Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.73 Top selling targeted therapies for Leukemia.
Table C.74 Molecules in Ph III clinical trials for Leukemia (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.75 Acute Myeloid Leukemia Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.76 Acute Myelogenous Leukemia Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.77 Acute Lymphoid Leukemia Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.78 Acute Lymphocytic Leukemia Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.79 Chronic Myeloid Leukemia Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.80 Chronic Myelogenous Leukemia Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.81 Chronic Myelomonocytic Leukemia Pipeline– Clinical stage drugs, developers, partners & targets.
Table C.82 Chronic Lymphoid Leukemia Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.83 Top selling targeted therapies for Non Hodgkin Lymphoma.
Table C.84 Molecules in Ph III clinical trials for Non Hodgkin Lymphoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.85 Non Hodgkin Lymphoma Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.86 Waldenstrom’s Macroglobulinemia– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.87 Molecules in Ph III clinical trials for Hodgkin Lymphoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.88 Hodgkin Lymphoma Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.89 Molecules in Ph III clinical trials for Brain Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.90 Glioblastoma Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.91 Neuroblastoma Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.92 Medullolastoma Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.93 Anaplastic Astrocytoma Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.94 Top selling targeted therapies for Head & Neck Cancer.
Table C.95 Molecules in Ph III clinical trials for Head & Neck Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.96 Head & Neck Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.97 Nasopharynx Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.98 Oral Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.99 Top selling targeted therapies for Renal Cell Carcinoma.
Table C.100 Molecules in Ph III clinical trials for Renal Cell Carcinoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.101 Renal Cell Carcinoma Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.102 Wilm’s Tumor Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.103 Top selling targeted therapies for Bladder Cancer.
Table C.104 Molecules in Ph III clinical trials for Bladder Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.105 Bladder Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.106 Top selling targeted therapies for Thyroid Cancer.
Table C.107 Molecules in Ph III clinical trials for Thyroid Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.108 Thyroid Cancer Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.109 Molecules in Ph III clinical trials for Sarcoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).
Table C.110 Sarcoma Pipeline– Clinical, Preclinical & Discovery stage drugs, developers, partners & targets).
Table C.111 Other Rare Cancer Indications Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.
Table C.112 Orphan Drug Status cancer molecules in clinical development (145 Molecules with 174 orphan indications)
(Drug Name, Phase, Orphan indication, developer, USFDA/EMEA approvals).
Table C.113 US FDA New Oncology Drug Approvals -2013 (Developer, month of approval, partner, drug proprietary name, established name, approved indications with disease state)
Table C.114 Oncology Clinical Pipeline- Major Drug Failures 2013 (Drug, Developer, month, phase, indications, comments).
Box C.1 Lung Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.2 Strong Clinical Pipeline Companies – Lung Cancer.
Box C.3 Breast Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.4 Strong Clinical Pipeline Companies – Breast Cancer.
Box C.5 Colorectal Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.6 Strong Clinical Pipeline Companies – Colorectal Cancer.
Box C.7 Melanoma Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.8 Strong Clinical Pipeline Companies – Melanoma Cancer.
Box C.9 Prostate Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.10 Strong Clinical Pipeline Companies – Prostate Cancer.
Box C.11 Ovarian Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.12 Strong Clinical Pipeline Companies – Ovarian Cancer.
Box C.13 Other Gynecologic Malignancies Indications.
Box C.14 Pancreatic Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.15 Strong Clinical Pipeline Companies – Pancreatic Cancer.
Box C.16 Other Gastrointestinal Indications.
Box C.17 Hepatocellular Carcinoma-An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.18 Gastric Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.19 Multiple Myeloma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.20 Leukemia- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.21 NonHodgkin Lymphoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.22 Hodgkin Lymphoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.23 Brain Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.24 Head & Neck Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.25 Renal Cell Carcinoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.26 Bladder Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.27 Thyroid Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Box C.28 Sarcoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.
Other Reports in this series
